Hypertrophy of the synovial membrane with the background of juvenile idiopathic arthritis under the mask of tenosynovial giant cell tumour: a clinical case report

  • Vladyslava Bespalova Student, Bogomolets National Medical University, Kyiv, Ukraine https://orcid.org/0009-0009-7394-4153
  • Liubov Petelytska Postdoctoral researcher in the Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland. Assistant Professor, Candidate of Medical Sciences, Department of Internal Medicine N3, Bogomolets National Medical University, Kyiv, Ukraine https://orcid.org/0000-0001-8330-8681
Keywords: Arthritis; Tenosynovial Giant Cell Tumor; Disease-Modifying Antirheumatic Drug; DMARD; Tumor; juvenile idiopathic

Abstract

juvenile idiopathic arthritis is the most common childhood rheumatologic disorder, characterized by chronic inflammation in the synovial joints. Its pathophysiology includes synoviocyte proliferation, pathological angiogenesis, and immune cell infiltration, leading to joint destruction and functional impairment. Tenosynovial giant cell tumor, a rare benign tumor affecting synovial tissues, often mimics juvenile idiopathic arthritis symptoms, complicating diagnosis. This case presents a 30-year-old male with a long history of juvenile idiopathic arthritis and recurrent uveitis, who was diagnosed with bilateral villonodular synovitis in the knee joints. Despite magnetic resonance imaging findings suggesting tenosynovial giant cell tumor, histopathological examination following knee arthroscopy revealed chronic moderate synovitis, confirming juvenile idiopathic arthritis pathology. The patient had not received disease-modifying antirheumatic drugs for several years, contributing to disease progression. The American College of Rheumatology highlights the importance of early disease-modifying antirheumatic drugs use, particularly methotrexate, to prevent joint damage in juvenile idiopathic arthritis. Delayed initiation of biologic disease-modifying antirheumatic drugs leads to poorer long-term outcomes, emphasizing the need for early intervention to control inflammation and prevent irreversible joint damage. This case underscores the diagnostic challenge of distinguishing juvenile idiopathic arthritis-related synovial hypertrophy from tenosynovial giant cell tumor and emphasizes the critical role of histopathological confirmation.

References

Muller LSO, Humphries P, Rosendahl K. The joints in juvenile idiopathic arthritis. Insights Into Imaging [Internet]. 2015 Apr 22;6(3):275–84. Available from: https://pubmed.ncbi.nlm.nih.gov/25903287/

Thatayatikom A, Modica R, De Leucio A. Juvenile idiopathic arthritis [Internet]. StatPearls - NCBI Bookshelf. 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK554605/

Zaripova LN, Midgley A, Christmas SE, Beresford MW, Baildam EM, Oldershaw RA. Juvenile idiopathic arthritis: from aetiopathogenesis to therapeutic approaches. Pediatric Rheumatology [Internet]. 2021 Aug 23;19(1). Available from: https://doi.org/10.1186/s12969-021-00629-8

Stagi S, Cavalli L, Signorini C, Bertini F, Cerinic M, Brandi M, et al. Bone mass and quality in patients with juvenile idiopathic arthritis: longitudinal evaluation of bone-mass determinants by using dual-energy x-ray absorptiometry, peripheral quantitative computed tomography, and quantitative ultrasonography. Arthritis Research & Therapy [Internet]. 2014 Jan 1;16(2):R83. Available from: https://doi.org/10.1186/ar4525

Gelhorn HL, Tong S, McQuarrie K, Vernon C, Hanlon J, Maclaine G, et al. Patient-reported symptoms of tenosynovial giant cell tumors. Clinical Therapeutics [Internet]. 2016 Apr 1;38(4):778–93. Available from: https://doi.org/10.1016/j.clinthera.2016.03.008

Choi WS, Lee SK, Kim JY, Kim Y. Diffuse-Type Tenosynovial Giant cell tumor: What are the important findings on the Initial and Follow-Up MRI? Cancers [Internet]. 2024 Jan 17;16(2):402. Available from: https://www.mdpi.com/2072-6694/16/2/402

Spierenburg G, Ballesteros CS, Stoel BC, Cañete AN, Gelderblom H, Van De Sande M a. J, et al. MRI of diffuse-type tenosynovial giant cell tumour in the knee: a guide for diagnosis and treatment response assessment. Insights Into Imaging [Internet]. 2023 Feb 1;14(1). Available from: https://doi.org/10.1186/s13244-023-01367-z

Ramos FO, Zinterl C, Fonseca JE. A lifelong journey: Long-term perspectives on Juvenile Idiopathic Arthritis. Best Practice & Research Clinical Rheumatology [Internet]. 2024 Jul 1;101984. Available from: https://doi.org/10.1016/j.berh.2024.101984

Guo Q, Wang Y, Xu D, Nossent J, Pavlos NJ, Xu J. Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. Bone Research [Internet]. 2018 Apr 25;6(1). Available from: https://doi.org/10.1038/s41413-018-0016-9

Bison HS, Janetos TM, Gao HM, Zhang DL, Song J, Bohnsack BL. Comparison of Uveitis incidence by medication in juvenile idiopathic arthritis and implications for screening. American Journal of Ophthalmology [Internet]. 2022 Nov 11;247:70–8. Available from: https://doi.org/10.1016/j.ajo.2022.11.010

Tappeiner C, Schenck S, Niewerth M, Heiligenhaus A, Minden K, Klotsche J. Impact of antiinflammatory treatment on the onset of uveitis in juvenile idiopathic arthritis: longitudinal analysis from a nationwide pediatric rheumatology database. Arthritis Care & Research [Internet]. 2015 Jul 24;68(1):46–54. Available from: https://doi.org/10.1002/acr.22649

Maccora I, Simonini G, Guly CM, Ramanan AV. Management of JIA associated uveitis. Best Practice & Research Clinical Rheumatology [Internet]. 2024 Jul 1;101979. Available from: https://doi.org/10.1016/j.berh.2024.101979

Spierenburg G, Van Der Heijden L, Van Langevelde K, Szuhai K, Bovée JVGM, Van De Sande MAJ, et al. Tenosynovial giant cell tumors (TGCT): molecular biology, drug targets and non-surgical pharmacological approaches. Expert Opinion on Therapeutic Targets [Internet]. 2022 Apr 3;26(4):333–45. Available from: https://doi.org/10.1080/14728222.2022.2067040

Published
2025-06-29
How to Cite
1.
Bespalova V, Petelytska L. Hypertrophy of the synovial membrane with the background of juvenile idiopathic arthritis under the mask of tenosynovial giant cell tumour: a clinical case report . USMYJ [Internet]. 2025Jun.29 [cited 2026Mar.21];154(2):83-0. Available from: https://mmj.nmuofficial.com/index.php/journal/article/view/518
Section
CLINICAL ANNUAL SCIENTIFIC EXPERIENCE (CASE)